Results 11 to 20 of about 1,448,905 (180)

Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways [PDF]

open access: yesJournal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic ...
Julie Langlois   +12 more
doaj   +2 more sources

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

open access: yesJAAD Case Reports
Shannon Meledathu, BS   +4 more
doaj   +2 more sources

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) [PDF]

open access: yesHemaSphere, 2023
Francesca Palandri   +13 more
doaj   +2 more sources

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor [PDF]

open access: yesJAAD Case Reports
Alison H. Kucharik, MD   +5 more
doaj   +2 more sources

Correction: Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma [PDF]

open access: yesJournal of Experimental & Clinical Cancer Research
Jin Wang   +7 more
doaj   +2 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

open access: yesFrontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song   +21 more
doaj   +1 more source

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

open access: yes, 2020
Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.
Christian Beerli   +33 more
core   +3 more sources

Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase

open access: yes, 2021
Although Bruton’s tyrosine kinase (BTK) has been recognized as a validated drug target for the treatment of B-cell malignances, the emergence of clinical resistance to the first-generation covalent BTK inhibitors is becoming a serious concern.
Masaaki Sawa (5801243)   +6 more
core   +2 more sources

Novel Bruton’s Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays

open access: yes, 2022
Bruton’s tyrosine kinase (BTK) is a well-documented target for cancer therapeutics due to its role in B-cell signaling pathways. However, inhibitor design is hindered by lack of tools to assess kinase activity.
Naomi E. Widstrom (12741873)   +7 more
core   +4 more sources

Home - About - Disclaimer - Privacy